Introduction
Reduced intensity conditioning (RIC) allogeneic haematopoietic stem cell transplantation (HSCT) is now a feasible treatment modality for both malignant and non-malignant diseases.
1 RIC HSCT relies on increased immunosuppression to ensure donor engraftment and prevention of graft rejection, with both chemotherapy and a graft-versusleukaemia (GvL) effect utilized to eliminate any residual malignant disease. 1 There have been many reports of clonal gammopathies (CG) post transplantation in both the myeloablative allogeneic and the autologous settings. 2, 3 This is thought to be related to immune dysregulation post-HSCT with delayed reconstitution of B-and T-cell lineages. 4 In particular, several groups have shown that graft-versus-host disease (GvHD) and severe infections may delay the normal restoration of the T-and B-cell immune repertoire, by inducing expansions of reactive clones, 5, 6 and that these factors may act as stimuli for the development of autoantibodies and CG. In addition, the more intensive immunosuppression associated with T celldepleting regimens is thought to increase the incidence of autoimmune disorders post transplantation. 7 We report a study of 138 consecutive patients with myeloid malignancies who underwent FBC (fludarabinebusulphan-alemtuzumab) RIC HSCT, where we prospectively monitored the development of CG and sought to correlate their presence with clinical parameters and subsequent transplant outcomes.
Patients and methods

Patient selection
A total of 138 consecutive patients underwent RIC HSCT at Kings College Hospital, London, between January 1998 and December 2004 (patient characteristics are listed in Table 1 ). The median patient age was 52 years (range: 22-72 years). Patients were treated for myelodysplastic syndromes (MDS) (96), acute myeloid leukaemia (AML) (31), chronic myeloid leukaemia (CML) (10) , and Krabbes disease (1) . Patients with autoimmune disorders or CG before transplant were excluded from the study. Patients were screened every 3 months by serum electrophoresis for the occurrence of CG. When CG were detected, further monitoring was performed on a monthly basis. Where gammopathies were detected, immunoglobulin subclasses were analysed by immunofixation electrophoresis. Bone marrow (BM) aspirates and trephines of patients with gammopathies were reviewed to exclude the presence of plasma cell dyscrasias. Our local institutional research ethics committee approved the study protocol, and informed consent was obtained from all participating patients.
Conditioning protocol, GvHD prophylaxis and chimerism analysis
The RIC protocol consisted of 30 mg/m 2 fludarabine i.v. daily from day À9 to day À5, 4 mg/kg busulphan in divided doses daily from day À3 to day À2 and 20 mg alemtuzumab i.v. daily from day À8 to day À4. Unselected PBSC or BM were infused on day 0. All patients received cyclosporin A for GvHD prophylaxis, and standard nursing and supportive care were given as described previously. 8 Chimerism was assessed by PCR and fluorescent analysis of short tandem repeat sequences on BM or whole blood using the Promega PowerPlex 16 System (Promega, Madison, WI, USA). Chimerism assessments were scheduled for days 28, 56 and 100, at 6 months and then yearly. Response assessment was made by morphological review, or where a karyotypic abnormality was present at diagnosis or before transplantation, by conventional cytogenetic analysis.
Statistical analysis
Differences between patient groups were evaluated using the w 2 test for categorical data, and the Mann-Whitney U-test for continuous data. Overall survival (OS) and relapse-free survival (RFS) curves were estimated by the Kaplan-Meier method for the entire study population and by univariate analysis (the log-rank test was used to compare survival curves between different subgroups). The Cox proportionate hazard model was used when estimating the simultaneous influence on those outcomes of two or more risk factors (predictors).
To calculate relapse incidence (REL), the incidence of CG, of acute GvHD (aGvHD) and chronic GvHD (cGvHD) a competing risk model was used. In each case, death (before the event under study) was used as the competing event (non-relapse mortality (NRM) was derived therefore from the REL competing risk analysis). The effect of any possible risk factor on either REL or NRM or CG or aGvHD or cGvHD was still estimated by using a COX model, where REL was treated as a censoring event for the end point 'death' and vice versa. Effects of risk factors are therefore always expressed as hazard ratios and their corresponding 95% confidence intervals.
Finally, the effect of the occurrence of CG and cGvHD on overall survival, relapse and non-relapse mortality was studied in the framework of a Cox model with both CG and cGvHD included as time-dependent covariates switching from absent to present at the precise moment of occurrence of the gammopathy and cGvHD, respectively. To test whether the effect of the occurrence of CG could depend on another risk factor, an interaction with that risk factor was added and tested for significance with the usual likelihood ratio test. In all cases where a Cox model was used, the model assumptions were verified by introducing a time-dependent categorical covariate switching from 0 to 1 at the median follow-up time of the uncensored observations. A P-value of less than 0.05 was considered to be significant.
Results
Incidence and characteristics of clonal gammopathies
Forty-nine patients (36%) developed a clonal gammopathy following transplantation. Gammopathies appeared at a median of 155 days (range; 45-833 days) following HSCT. Thirty-one patients experienced transient gammopathies, which lasted for a median of 187 days (range: 36-390 days). On analysis of immunoglobulin subclasses, the M component was identified as monoclonal in 21 (43%), biclonal in 16 (33%) and oligoclonal in 12 cases (24%). The Ig isotype identified was predominantly IgG (n ¼ 40, 82%), followed by IgM (n ¼ 2) and IgA (n ¼ 1). In six cases, the Ig isotype was not identified. The k/l ratio between samples was 1.65:1. The median level of gammopathies was 0.26 g/dl (range: 0.1-1.65 g/dl). When the characteristics of the group were compared with those of the cohort of patients without gammopathies, there were no significant differences in donor or recipient age, sex, disease type, stem cell source or stem cell dose.
Cyclosporin A was tapered off at a median of 64 days post-transplant (range: 36-204 days). Six patients (12%) were receiving cyclosporin A at the time of evolution of gammopathy. The incidence of viral infections was similar between the groups. Thirteen patients (27%) with CG developed cytomegalovirus (CMV) reactivation and one patient had reactivation of hepatitis B post-transplant. In 10 of these cases, the viral infection preceded detection of the gammopathy. In addition, 10 patients (20%) developed autoimmune disorders (cytopenias or thyroid disease) of whom three had concurrent gammopathy. There was, however, no association between the presence of an autoimmune disorder and a gammopathy (P ¼ 0.51).
BM chimaerism was available for analysis on 42/49 patients (86%). At the time of detection of gammopathy, 33 patients (79%) had achieved full donor chimaerism (495% donor chimaerism), and 9 (21%) had mixed donor chimaerism (15-95% donor chimaerism), with no correlation between chimaerism status and development of the gammopathy. At time of follow-up, eight patients had died (relapse n ¼ 4, infections n ¼ 2, GvHD n ¼ 1, cardiac arrest out of hospital n ¼ 1).
The cumulative incidence of acute and chronic GvHD in the cohort at 2 years was 28 and 23%, respectively. On further analysis, there was a significant correlation between the presence of a gammopathy and prior cGvHD, in those who had cGvHD having a 2.7-fold higher risk of developing a clonal gammopathy (95% CI (1.3-5.5), Po0.001; cGvHD treated as a time-dependent covariate with the occurrence of CG as end point). The same could not be shown for aGvHD, which showed a hazard ratio of only 1.4 (P ¼ 0.46) in the corresponding Cox model.
Overall outcomes
The 2-year OS and RFS for the entire cohort were 54 and 42%. In addition, the estimated NRM and REL at 2 years is 20 and 36%, respectively. Cumulative incidence curves accounting for the competing risks of NRM and relapse are illustrated in Figure 1a .
On multivariate analysis, the only factors that were found to influence OS were presence of paraproteinaemia, which was associated with an improved OS (OR 0.35 95% CI 0.14-0.86, P ¼ 0.02) as well as disease stage, with patients with advanced disease having a higher risk of death (OR 2.20 95% CI 1.18-4.11, P ¼ 0.13). Disease stage was the only variable that influenced REL on multivariate analysis (Table 2 ) (OR 4.22 95% CI 1.82-9.78, P ¼ 0.001). For non-relapse related mortality, disease stage (P ¼ 0.21), disease type (P ¼ 0.88) or the presence of paraproteinaemia (P ¼ 0.30) did not influence outcome on multivariate analysis. In addition, the presence or absence of chronic GvHD was not significantly associated with relapse (P ¼ 0.76), non-relapse mortality (P ¼ 0.67) or overall survival (P ¼ 0.49). Figures 1b and c demonstrate cumulative incidence estimates of CG and chronic GvHD, respectively, from a competing risk model considering death as a competing risk in both cases.
Discussion and conclusion
The presence of monoclonal gammopathies has been reported following both conventional myeloablative HSCT and autologous HSCT with a prevalence which varies from 10 to 90% depending on the sensitivity of the assay. [9] [10] [11] Hitherto, the occurrence of CG in the setting of RIC HSCT has not been clearly defined. Here, we demonstrate that CG are frequent (36% incidence) using an alemtuzumab-based regimen, and are closely associated with the presence of chronic GvHD and improved overall survival.
Although haematopoietic recovery happens rapidly following RIC allografting, there is evidence that regeneration of T-and B-cell function may be delayed. 6, 11 In the context of RIC HSCT, the choice of T cell-depleting agent may influence the pattern of recovery of T cells. 6, 12 Alemtuzumab (CAMPATH 1H) is a recombinant humanized IgG antibody against CD52. When used in vivo as a preparative regimen for allogeneic HSCT, alemtuzumab depletes both host and donor T cells as well as dendritic cells, and has been shown to promote engraftment and reduce the incidence and severity of GvHD. 13 A recent study by Loh and collegues in patients with autoimmune diseases undergoing autologous HSCT found that patients receiving an alemtuzumab-based regimen had a higher incidence of secondary autoimmune complications when compared to patients receiving either an anti-thymocyte globulin-based T cell-depleting regimen or those who received no T cell depletion. 7 In addition, autoimmune cytopenias occur more frequently in patients treated with fludarabine, 14 and the combined effect of fludarabine and alemtuzumab in conditioning regimens may contribute to immune dysregulation and autoimmunity.
Exposure to specific events post-HSCT such as infection, GvHD and immunosuppression can promote development of dominant B-or T-cell clones with skewing of the recovering immune repertoire. [4] [5] [6] 15 There have been various observational reports on the development of autoantibodies and gammopathies post-HSCT coinciding with CMV reactivation or presence of GvHD. 16 Indeed, viral infections have been associated with the development of chronic GvHD or autoimmunity through various mechanisms such as aberrant expression of intracellular antigens on virus-infected cells triggering a specific immune response, or molecular mimicry between virally encoded peptides and self-peptides. 17 While the use of alemtuzumabbased RIC regimens has been associated with an increased incidence of viral infections post-HSCT, 18, 19 in our cohort, there was no increased incidence of viral infections between patients with and without gammopathies (P ¼ 0.431). Polyclonal B-cell stimulation by Epstein-Barr virus, particularly in the context of T cell-depleted HSCT, often predisposes the development of post-transplant lymphoproliferative disorder (PTLD). 20 However, no patients in this cohort developed PTLD.
There is increasing evidence to suggest that chronic GvHD shares many similarities with autoimmune disorders. 15, 16 T cells and dendritic cells play an important role in B-cell maturation and the development of humoral response, and antibody responses against minor histocompatibility antigens such as H-Y antigens have been implicated in chronic GvHD and GvL effect following HSCT. 21 The role of humoral responses following transplantation is still undefined. While there was a significant association between the presence of CG and chronic GvHD, it remains possible that the CG seen in our cohort are a surrogate response to a heterogenous group of stimuli. With the increasing popularity of RIC HSCT, it is of relevance for transplant physicians to recognize that CG are a frequent but benign occurrence post RIC HSCT. Further studies are warranted into the kinetics of B-cell reconstitution following RIC HSCT. 
